Cumberland Pharmaceuticals Inc. filings document a specialty pharmaceutical issuer with branded prescription products and clinical-development programs. The company's 8-K reports cover operating and financial results, FDA and clinical regulatory updates, material agreements, credit-facility amendments, capital-structure disclosures and other material events tied to its pharmaceutical portfolio.
Proxy materials and annual-meeting reports disclose board elections, auditor ratification, advisory compensation votes, executive compensation, beneficial ownership, corporate governance and shareholder proposal procedures. Financing-related filings describe revolving credit obligations, borrowing covenants, collateral arrangements and related debt disclosures.
Cumberland Pharmaceuticals vice president receives new stock options grant. Vice President of Organizational Development Anthony Todd M. was granted options to acquire 3,000 shares of Cumberland Pharmaceuticals common stock at an exercise price of $2.80 per share. These options become exercisable on March 18, 2030 and expire on March 18, 2036. Following this award, his reported derivative holdings total 21,000 options.
Bitterman Chris T. reported acquisition or exercise transactions in this Form 4 filing.
Cumberland Pharmaceuticals vice president of sales and marketing Chris T. Bitterman received a grant of options to buy 3,000 shares of common stock at $2.80 per share. These options become exercisable on March 18, 2030 and expire on March 16, 2036. Following this award, he holds options covering 19,000 shares in total.
Cumberland Pharmaceuticals Vice President and Chief Financial Officer John M. Hamm received a grant of 3,000 stock options on March 18, 2026. These options carry an exercise price of $2.80 per share and expire on March 18, 2036, bringing his reported option holdings to 18,250 shares.
Cumberland Pharmaceuticals executive James L. Herman received a grant of 2,500 stock options linked to the company’s common stock. The options carry an exercise price of 2.80 per share, become exercisable on 2030-03-18, and expire on 2036-03-18.
After this award, Herman holds a total of 21,000 options directly. This is a routine compensation-related grant rather than an open-market purchase or sale, so it does not reflect new trading activity in the company’s stock.
Cumberland Pharmaceuticals Chairman and CEO A. J. Kazimi received a grant of stock options covering 100,000 shares of common stock at an exercise price of $2.8000 per share. After this award, he holds options for a total of 568,000 shares, reflecting compensation rather than an open-market purchase.
Cumberland Pharmaceuticals chairman and CEO A.J. Kazimi reported a tax-related share disposition. On this Form 4, 5,845 shares of Common Stock were withheld at $3.06 per share to cover tax obligations. After this non-market transaction, he directly holds 5,695,310 shares of Cumberland Pharmaceuticals.
Cumberland Pharmaceuticals Inc. has issued its definitive proxy for the 2026 Annual Meeting, to be held April 21, 2026 at its Nashville headquarters. Shareholders will vote on electing two Class I directors (Kenneth Krogulski and Caroline Young), ratifying Carr, Riggs & Ingram, L.L.C. as auditor for 2026, an advisory “say‑on‑pay” vote on executive compensation, and an advisory vote on how often to hold future say‑on‑pay votes.
The Board recommends voting for all proposals and for holding say‑on‑pay votes every three years. The company discloses 2025 executive pay, highlights 20% revenue growth with higher adjusted earnings and cash flow, and reports a CEO pay ratio of 10:1, with the CEO beneficially owning 38.43% of outstanding common stock.
Cumberland Pharmaceuticals Inc. files its annual report describing a specialty pharmaceutical business focused on hospital acute care, gastroenterology and oncology. The company markets seven FDA-approved brands, including Acetadote for acetaminophen poisoning, Caldolor for pain and fever, Kristalose for constipation, Vibativ for serious infections, Sancuso for chemotherapy-induced nausea, Vaprisol for hyponatremia and Talicia for H. pylori.
Cumberland highlights expanding clinical data and labeling for Caldolor, new access agreements for Vibativ, and a U.S. co-commercialization structure for Talicia through Talicia Holdings Inc. Its ifetroban candidate showed positive Phase II results in Duchenne muscular dystrophy cardiomyopathy and is in additional Phase II trials for systemic sclerosis and idiopathic pulmonary fibrosis, supported by orphan, rare pediatric and fast track designations. The company also emphasizes international partnerships, sustainability metrics and disciplined expense management.
Cumberland Pharmaceuticals reported strong 2025 growth with improving profitability and cash generation. Net revenues reached $44.5 million for 2025, up 18% year over year, including $13.7 million in fourth-quarter revenue, a 31% increase over the prior-year quarter. Key brands contributed $10.5 million from Kristalose, $11.9 million from Sancuso, $9.5 million from Vibativ, $4.7 million from Caldolor and $3.3 million from Talicia.
The company’s 2025 net loss narrowed to $2.9 million, a $3.6 million improvement from 2024, while Adjusted Earnings were $1.7 million, a $2.7 million improvement. Operating cash flow turned positive at $4.9 million. At December 31, 2025, Cumberland reported $76.8 million in total assets, $52.3 million in liabilities and $24.9 million in shareholders’ equity, including $11.4 million in cash and a reduced credit facility balance of $5.2 million, down $10 million from year-end 2024.
Strategically, Cumberland expanded Vibativ into China and Saudi Arabia, gained approval for an ibuprofen injection in Mexico, and added Talicia via a co-commercialization agreement. Caldolor received a permanent CMS J-code (J1741), and the ifetroban FIGHT DMD Phase II trial delivered positive top-line results, with the DMD program receiving Orphan Drug, Rare Pediatric Disease and Fast Track designations.